Table 3.
Individual efficacy data depending on HCV genotype, hepatic fibrosis, and primary and rescue regimen.
| Patient | Fibrosis | GT | Primary regimen | Response to primary reg. | Months between therapies | Rescue regimen | Response to rescue reg. |
|---|---|---|---|---|---|---|---|
| 1 | 4 | 3 | OBV/PTV/r+DSV+RBV | REL | 6 | LDV/SOF+RBV, 12wks | NR |
| 2 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 1wk | 1 | LDV/SOF+RBV, 12wks | SVR |
| 3 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 2wks | 11 | LDV/SOF, 12wks | LFU |
| 4 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 3wks | 11 | LDV/SOF, 24wks | SVR |
| 5 | 1 | 1B | OBV/PTV/r+DSV | DSC, 4 wks | 5 | LDV/SOF, 12wks | SVR |
| 6 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 4 wks | 2 | LDV/SOF, 24wks | SVR |
| 7 | 1 | 1B | OBV/PTV/r+DSV | DSC, 1 wk | 2 | LDV/SOF, 12wks | SVR |
| 8 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 2wks | 17 | LDV/SOF, 12wks | SVR |
| 9 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 3wks | 10 | LDV/SOF+RBV, 12wks | SVR |
| 10 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 4wks | 9 | LDV/SOF, 24wks | SVR |
| 11 | 3 | 1B | OBV/PTV/r+DSV | NR | 12 | LDV/SOF+RBV, 12wks | SVR |
| 12 | 1 | 1B | OBV/PTV/r+DSV | DSC, 1 day | 7 | LDV/SOF, 8wks | SVR |
| 13 | 4 | 3 | SOF+RBV | REL | 3.5 | SOF+DCV, 12wks → SOF+RBV, 12wks |
SVR |
| 14 | 2 | 4 | SOF+RBV | NR | 6 | GZR/EBR, 12wks | SVR |
| 15 | 4 | 3 | SOF+RBV | REL | 8 | SOF+DCV+RBV 24wks | SVR |
| 16 | 4 | 1B | LDV/SOF+RBV | REL | 9 | LDV/SOF+RBV, 24wks | NR |
| 17 | 4 | 4 | LDV/SOF+RBV | REL | 8 | GZR/EBR, 12wks | LFU |
| 18 | 3 | 4 | LDV/SOF | NR | 16 | OBV/PTV/r+RBV, 24wks | SVR |
| 19 | 2 | 1B | LDV/SOF | REL | 16 | OBV/PTV/r+DSV, 12wks | SVR |
| 20 | 0 | 4 | LDV/SOF | REL | 7 | GZR/EBR+RBV, 16wks | SVR |
| 21 | 4 | 1B | LDV/SOF+RBV | NR | 17 | LDV/SOF+RBV, 24wks | SVR |
| 22 | 4 | 1B | LDV/SOF+RBV | NR | 14 | SOF+DCV+RBV 24wks | NR |
| 23 | 4 | 1B | ASV+DCV | NR | 4 | OBV/PTV/r+DSV+RBV, 12wks | NR |
| 24 | 4 | 4 | ASV+DCV | UKN | 0 | OBV/PTV/r+RBV, 24wks | SVR |
| 25 | 4 | 1B | ASV+DCV | NR | 12 | LDV/SOF+RBV, 24wks | SVR |
| 26 | 4 | 1B | SMV+SOF+RBV | REL | 13 | LDV/SOF+RBV, 24wks | SVR |
| 27 | 4 | 1B | SOF+DCV+RBV | NR | 4 | GZR/EBR, 12wks | SVR |
| 28 | 4 | 1B | OBV/PTV/r+DSV+RBV | DSC, 4wks | 12 | LDV/SOF, 24wks | SVR |
| 29 | 4 | 1B | OBV/PTV/r+DSV+RBV | REL | 12 | LDV/SOF, 24wks | SVR |
| 30 | 4 | 1B | OBV/PTV/r+DSV+RBV | REL | 7 | LDV/SOF, 24wks | SVR |
| 31 | 2 | 1B | ASV+DCV | NR | 18 | OBV/PTV/r+DSV+RBV, 12wks | SVR |
GT: genotype; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; GZR: grazoprevir; EBR: elbasvir; REL: relapse; DSC: discontinued; NR: nonresponder, UKN: unknown; LFU: lost to follow-up.